{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:21:24Z","timestamp":1770909684627,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gilead Sciences K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40121-024-00997-0","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:02:25Z","timestamp":1716994945000},"page":"1607-1620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy"],"prefix":"10.1007","volume":"13","author":[{"given":"Yasuhito","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryozo","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung min","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"issue":"5","key":"997_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1440-1746.2010.06243.x","volume":"25","author":"JS Lubel","year":"2010","unstructured":"Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25(5):864\u201371.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"997_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1136\/gut.2009.195834","volume":"59","author":"K Wursthorn","year":"2010","unstructured":"Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut. 2010;59(10):1430\u201345.","journal-title":"Gut"},{"issue":"1","key":"997_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182\u20138.","journal-title":"Gastroenterology"},{"issue":"3","key":"997_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299\u2013307.","journal-title":"J Med Virol"},{"issue":"10","key":"997_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1445-5994.2007.01479.x","volume":"37","author":"JS Lubel","year":"2007","unstructured":"Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37(10):705\u201312.","journal-title":"Intern Med J"},{"issue":"9","key":"997_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","volume":"29","author":"MB Carroll","year":"2010","unstructured":"Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29(9):1021\u20139.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"997_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/s10165-010-0337-z","volume":"21","author":"Y Urata","year":"2011","unstructured":"Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21(1):16\u201323.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"997_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.780","volume":"11","author":"X Hong","year":"2023","unstructured":"Hong X, Xiao Y, Xu L, Liu L, Mo H, Mo H. Risk of hepatitis B reactivation in HBsAg-\/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: a meta-analysis. Immun Inflamm Dis. 2023;11(2): e780.","journal-title":"Immun Inflamm Dis"},{"issue":"24","key":"997_CR9","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.3748\/wjg.v23.i24.4317","volume":"23","author":"I Aggeletopoulou","year":"2017","unstructured":"Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol. 2017;23(24):4317\u201323.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"997_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40249-023-01128-6","volume":"12","author":"Z Xia","year":"2023","unstructured":"Xia Z, Zhang J, Chen W, Zhou H, Du D, Zhu K, et al. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Infect Dis Poverty. 2023;12(1):87.","journal-title":"Infect Dis Poverty"},{"issue":"9","key":"997_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/hepr.13798","volume":"52","author":"S Hagiwara","year":"2022","unstructured":"Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, et al. Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection. Hepatol Res. 2022;52(9):754\u201361.","journal-title":"Hepatol Res"},{"issue":"5","key":"997_CR12","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1086\/590968","volume":"47","author":"T Umemura","year":"2008","unstructured":"Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47(5):e52\u20136.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"997_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s12072-022-10301-2","volume":"16","author":"G Lau","year":"2022","unstructured":"Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, et al. Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2022;16(2):486\u20137.","journal-title":"Hepatol Int"},{"issue":"5","key":"997_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/MCG.0000000000001520","volume":"55","author":"Y Wang","year":"2021","unstructured":"Wang Y, Han SHB. Hepatitis B reactivation: a review of clinical guidelines. J Clin Gastroenterol. 2021;55(5):393\u20139.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"997_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/hepr.13504","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the management of hepatitis B virus infection: 2019update. Hepatol Res. 2020;50(8):892\u2013923.","journal-title":"Hepatol Res"},{"issue":"5","key":"997_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61(5):719\u201329.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"997_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s10147-016-0995-8","volume":"21","author":"M Ikeda","year":"2016","unstructured":"Ikeda M, Yamamoto H, Kaneko M, Oshima H, Takahashi H, Umemoto K, et al. Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan. Int J Clin Oncol. 2016;21(6):1162\u20136.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"997_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1620\/tjem.233.129","volume":"233","author":"R Watanabe","year":"2014","unstructured":"Watanabe R, Ishii T, Kobayashi H, Asahina I, Takemori H, Izumiyama T, et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med. 2014;233(2):129\u201333.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"997_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med. 2021;22(3):118\u201327.","journal-title":"J Gen Fam Med"},{"issue":"6","key":"997_CR20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s00535-017-1394-2","volume":"53","author":"M Nakao","year":"2018","unstructured":"Nakao M, Nakayama N, Uchida Y, Tomiya T, Ido A, Sakaida I, et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol. 2018;53(6):752\u201369.","journal-title":"J Gastroenterol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00997-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:29:28Z","timestamp":1719898168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00997-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00997-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuhito Tanaka received honoraria from Gilead Sciences Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Holdings Co., Ltd., OTSUKA Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, GlaxoSmithKline PLC., and GlaxoSmithKline PLC.; research funding from Gilead Sciences, Inc., AbbVie GK., FUJIREBIO Inc., Sysmex Corp., Janssen Pharmaceutical K.K. and GlaxoSmithKline PLC. Daisuke Nakamoto, Yi Piao, Hajime Mizutani, Kyung min Kwon, and Harriet Dickinson are current employees of Gilead Sciences with stock ownership. Yoshiyuki Saito is a board member of Datack Inc. with stock ownership.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted following the World Medical Association\u2019s Declaration of Helsinki, respecting the ethical standards for research involving human participants. This study did not require patient consent or approval from an institutional review board and independent ethics committee because the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects do not apply to studies exclusively on de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}